Untangling the Web of Antiretroviral Price Reductions. 16th Edition, July 2013
(2013; 100 pages)

Resumen

With nearly 10 million people now receiving treatment for HIV – and another 26 million eligible to receive it – the price of antiretroviral (ARV) drugs to put people on treatment remains a critical one.The 16th edition of Untangling the Web finds that although the price of first- and second-line ARVs have come down thanks to increased generic competition, third-line or salvage regimens remain exorbitantly priced, with middle-income countries such as Armenia paying more than US$13,000 per person per year for raltegravir, just one of the three or four drugs needed in a third-line cocktail.Patents remain a barrier on newer drugs and in middle-income countries, and will need to be overcome to ensure future access to them.

 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018